 |
|
|
|
|
|
| Highlights, achievements and key facts |
|
|
|
|
| |
|
|
|
|
|
- Over the past year, Aspen grew its market share in
all segments of the South African market in which it
performs, realising 30% revenue growth.
- Exports from South Africa amounted to almost
R600 million in 2009.
- Aspen announced that it had entered into a series
of strategic, inter-dependent transactions with
GlaxoSmithKline Group Ltd ("GSK"). The transactions,
once completed, are expected to be earnings accretive
from the outset.
- Aspen's revenue grew by 80% to R8,5 billion with
all segments of the business contributing to this
achievement.
- The South African private pharmaceutical market grew
at 15% in value terms to
R19,8 billion, while Aspen grew
at 20%.
- The eye drop suite in the Sterile Facility in Port Elizabeth
was completed and exports of Clear Eyes and Murine
have commenced to the United States.
- Revenue from international businesses increased from
R1,1 billion to R3,9 billion while operating profit rose
from R0,2 billion to
R1,0 billion.
- Aspen increased its shareholding to 51% in the businesses
in Brazil, Mexico and Venezuela. Full ownership will be
achieved during the year ahead.
- In Brazil 160 new sales representatives were appointed
and initiatives were implemented to increase the sales
forces in Mexico and Venezuela.
|
|
| |
|
|
|
|
|
| |
|
|
